<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116934</url>
  </required_header>
  <id_info>
    <org_study_id>PLS-Cytokines</org_study_id>
    <nct_id>NCT01116934</nct_id>
  </id_info>
  <brief_title>Cytokines in Papillon-Lefèvre Syndrome</brief_title>
  <official_title>Observational Study on Cytokine Production by Leukocytes of Papillon-Lefèvre Syndrome Patients and Healthy Probands in Whole Blood Cultures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goethe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goethe University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Papillon-Lefèvre syndrome (PLS) is characterised by aggressively progressive periodontitis
      combined with palmo-plantar hyperkeratosis. It is caused by &quot;loss of function&quot; mutations in
      the cathepsin C gene. The hypothesis behind this study is that PLS patients' PMNs produce
      more proinflammatory cytokines to compensate for their reduced capacity to neutralize
      leukotoxin and to eliminate Aggregatibacter actinomycetemcomitans. Production of more
      interleukin (IL)-8 would result in the attraction of more PMNs. Thus, the aim of this study
      was to evaluate the cytokine profile in PLS patients' blood cultures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MATERIAL AND METHODS Materials Lipopolysaccharide (LPS; Escherichia coli, serotype R515) was
      purchased from Alexis (Lausen, Switzerland) and adenosine triphosphate (ATP) from Sigma
      (Deisenhofen, Germany). Tumor necrosis factor α (TNF-α) was kindly provided by the Knoll AG
      (Ludwigshafen, Germany). IL-1β was from Invitrogen/Biosource (Karlsruhe, Germany).

      Patients and healthy donors Five patients with established diagnose of PLS are under
      periodontal treatment at the Department of Periodontology, Center for Dental, Oral, and
      Maxillofacial Medicine (Carolinum) of the Johann Wolfgang Goethe-University Frankfurt am
      Main. Antiinfective therapy with adjunctive antibiotics has been rendered to all of them and
      they are under regular and frequent supportive therapy. The Department of Periodontology has
      contact to additional 5 PLS patients that are edentulous or under periodontal therapy
      elsewhere. All patients underwent complete oral examinations as well as inspection of the
      skin of the palms and soles. Each adult patient or parents received clinical and genetic
      counselling, and signed a consent form, approved by the ethic committees of the Universities
      of Dresden and Frankfurt/Main. Clinical data and mutations of all patients have been reported
      before. All these patients were invited to take part in this study. Healthy donors had
      abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral
      contraceptives only male probands were chosen. The study complied with the rules of the
      Declaration of Helsinki and was approved by the Institutional Review Board for Human Studies
      of the Medical Faculty of the Johann Wolfgang Goethe-University Frankfurt/Main (Application#
      31/05). All participating individuals were informed on risks and benefit as well as the
      procedures of the study and gave written informed consent.

      Whole blood culture Heparinized blood was mixed with an equal volume of culture medium (RPMI
      1640 supplemented with 25 mM HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid),
      100 U/ml penicillin, 100 µg/ml streptomycin) and 1 ml aliquots were transferred into loosely
      sealed round-bottom polypropylene tubes (Greiner, Germany). Whole blood cultures were kept at
      37 oC and 5 % CO2 for the indicated time periods. Thereafter, cell-free plasma/RPMI samples
      were obtained by centrifugation and stored at -70oC until assessment of cytokine
      concentrations by enzyme linked immunosorbent essay (ELISA). Experiments were started within
      60 min of blood withdrawal. Thus, the whole blood cultures consisted of the whole range of
      white blood cells as well as erythrocytes. Except for determination of IL-1β release,
      cultures were either kept as unstimulated control or stimulated with LPS (10 or 100 ng/ml),
      or with the combination of IL-1β plus TNF-α (50 ng/ml each) for 24h. For determination of
      IL-1β release, cells were kept as unstimulated control or were stimulated with Toll-like
      receptor 4 ligand LPS (100 ng/ml) for altogether 5h. For efficient release of IL-1β from
      activated cultures, LPS was combined with ATP (2 mM) which was added during the last 2h of
      the 5h stimulation period in order to achieve activation of the purinoreceptor P2X7.

      Analysis of cytokine release by ELISA analysis Concentrations of IL-8, IL-6,
      interferon-inducible protein (IP)-10, interferon (IFN) gamma (Pharmingen/BD Biosciences), and
      IL-1β, (R&amp;D Systems), in plasma/RPMI samples were determined by ELISA according to the
      manufacturers' instructions.

      Statistics The individual patient or proband was defined as statistical unit. Data are shown
      as median with interquartile range and are presented as pg/ml (IL-1β, IL-6, IP-10) or as
      ng/ml (IL-8). Medians were compared between PLS patients and healthy volunteers using the non
      parametric Mann Whitney U test. Statistical analysis was performed using a computer program
      (Systat for Windows version 10.0, Systat Inc., Evanston, IL, USA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Concentrations of Interleukin (IL)-1 Beta</measure>
    <time_frame>2006</time_frame>
    <description>Concentrations of IL-8, IL-6, IP-10, interferon (IFN)-gamma, and IL-1 beta, in plasma/RPMI samples were determined by enzyme linked immunosorbent assay (ELISA) according to the manufacturers' instructions</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">17</enrollment>
  <condition>Papillon-Lefevre Disease</condition>
  <arm_group>
    <arm_group_label>PLS patients</arm_group_label>
    <description>Eight PLS patients (one female) from 6 families.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        5 patients with established diagnose of PLS are under periodontal treatment at the
        Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine
        (Carolinum) of the JWG-University Frankfurt am Main. Antiinfective therapy with adjunctive
        antibiotics has been rendered to all of them and they are under regular and frequent
        supportive therapy. The Department of Periodontology has contact to additional 5 PLS
        patients that are edentulous or under periodontal therapy elsewhere.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnose of PLS

        Exclusion Criteria:

          -  No written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Eickholz, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>JWG-University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine (Carolinum), JWG-University</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Eickholz P, Kugel B, Pohl S, Näher H, Staehle HJ. Combined mechanical and antibiotic periodontal therapy in a case of Papillon-Lefèvre syndrome. J Periodontol. 2001 Apr;72(4):542-9.</citation>
    <PMID>11338309</PMID>
  </reference>
  <reference>
    <citation>Noack B, Görgens H, Hoffmann T, Fanghänel J, Kocher T, Eickholz P, Schackert HK. Novel mutations in the cathepsin C gene in patients with pre-pubertal aggressive periodontitis and Papillon-Lefèvre syndrome. J Dent Res. 2004 May;83(5):368-70.</citation>
    <PMID>15111626</PMID>
  </reference>
  <reference>
    <citation>Lux CJ, Kugel B, Komposch G, Pohl S, Eickholz P. Orthodontic treatment in a patient with Papillon-Lefèvre syndrome. J Periodontol. 2005 Apr;76(4):642-50.</citation>
    <PMID>15857107</PMID>
  </reference>
  <reference>
    <citation>Schacher B, Baron F, Ludwig B, Valesky E, Noack B, Eickholz P. Periodontal therapy in siblings with Papillon-Lefèvre syndrome and tinea capitis: a report of two cases. J Clin Periodontol. 2006 Nov;33(11):829-36. Epub 2006 Sep 13.</citation>
    <PMID>16970621</PMID>
  </reference>
  <reference>
    <citation>Noack B, Görgens H, Schacher B, Puklo M, Eickholz P, Hoffmann T, Schackert HK. Functional Cathepsin C mutations cause different Papillon-Lefèvre syndrome phenotypes. J Clin Periodontol. 2008 Apr;35(4):311-6. doi: 10.1111/j.1600-051X.2008.01201.x. Epub 2008 Feb 20.</citation>
    <PMID>18294227</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <results_first_submitted>June 1, 2015</results_first_submitted>
  <results_first_submitted_qc>February 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2016</results_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Goethe University</investigator_affiliation>
    <investigator_full_name>Peter Eickholz</investigator_full_name>
    <investigator_title>Prof. Dr. med. dent.</investigator_title>
  </responsible_party>
  <keyword>blood culture, IL-1β, IL-6, IL-8, IP-10, interferon-gamma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillon-Lefevre Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Papillon-Lefèvre Syndrome (PLS) Patients</title>
          <description>8 PLS patients (one female) from 6 families</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls</title>
          <description>9 healthy donors</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PLS Patients</title>
          <description>8 PLS patients (one female) from 6 families</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls</title>
          <description>9 healthy donors</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Concentrations of Interleukin (IL)-1 Beta</title>
        <description>Concentrations of IL-8, IL-6, IP-10, interferon (IFN)-gamma, and IL-1 beta, in plasma/RPMI samples were determined by enzyme linked immunosorbent assay (ELISA) according to the manufacturers’ instructions</description>
        <time_frame>2006</time_frame>
        <population>Samples were stimulated with 100 ng/ml lipopolysaccharide (LPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Papillon-Lefèvre Syndrome (PLS) Patients</title>
            <description>8 PLS patients (one female) from 6 families</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>9 healthy donors</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Interleukin (IL)-1 Beta</title>
          <description>Concentrations of IL-8, IL-6, IP-10, interferon (IFN)-gamma, and IL-1 beta, in plasma/RPMI samples were determined by enzyme linked immunosorbent assay (ELISA) according to the manufacturers’ instructions</description>
          <population>Samples were stimulated with 100 ng/ml lipopolysaccharide (LPS)</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>interleukin-1 beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100.00" lower_limit="896.21" upper_limit="2572.10"/>
                    <measurement group_id="O2" value="896.21" lower_limit="771.15" upper_limit="2014.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>interleukin-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65559" lower_limit="40365" upper_limit="108260"/>
                    <measurement group_id="O2" value="45734" lower_limit="34056" upper_limit="66365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>interferon-inducible protein-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12902.5" lower_limit="8105.5" upper_limit="15735.5"/>
                    <measurement group_id="O2" value="11563" lower_limit="9164" upper_limit="19758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>interferon gamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3704.5" lower_limit="2629.5" upper_limit="4372.8"/>
                    <measurement group_id="O2" value="3317.4" lower_limit="2538.5" upper_limit="5487.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>interleukin-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50520" lower_limit="29280" upper_limit="79870"/>
                    <measurement group_id="O2" value="44390" lower_limit="24680" upper_limit="46580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were asked to report AEs from blood sampling if they occured.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PLS Patients</title>
          <description>8 PLS patients (one female) from 6 families</description>
        </group>
        <group group_id="E2">
          <title>Healthy Controls</title>
          <description>9 healthy donors</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Peter Eickholz</name_or_title>
      <organization>JWGUniversity</organization>
      <phone>+49-69-6301 ext 5642</phone>
      <email>eickholz@med.uni-frankfurt.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

